EP3411068A4 - Bispecific binding proteins for pd-l1 and kdr - Google Patents

Bispecific binding proteins for pd-l1 and kdr Download PDF

Info

Publication number: EP3411068A4
Authority: EP; European Patent Office
Prior art keywords: kdr; binding proteins; bispecific binding; bispecific; proteins
Prior art date: 2016-02-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17748163.7A

Other languages

German (de)

French (fr)

Other versions

EP3411068A2 (en

Inventor

Zhenping Zhu

Dan Lu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kadmon Corp LLC

Original Assignee

Kadmon Corp LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-02

Filing date

2017-02-02

Publication date

2020-01-29

2017-02-02 Application filed by Kadmon Corp LLC filed Critical Kadmon Corp LLC

2018-12-12 Publication of EP3411068A2 publication Critical patent/EP3411068A2/en

2020-01-29 Publication of EP3411068A4 publication Critical patent/EP3411068A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP17748163.7A 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr Withdrawn EP3411068A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662290350P	2016-02-02	2016-02-02
PCT/US2017/016230 WO2017136562A2 (en)	2016-02-02	2017-02-02	Bispecific binding proteins for pd-l1 and kdr

Publications (2)

Publication Number	Publication Date
EP3411068A2 EP3411068A2 (en)	2018-12-12
EP3411068A4 true EP3411068A4 (en)	2020-01-29

Family

ID=59501012

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17748163.7A Withdrawn EP3411068A4 (en)	2016-02-02	2017-02-02	Bispecific binding proteins for pd-l1 and kdr

Country Status (5)

Country	Link
EP (1)	EP3411068A4 (en)
JP (1)	JP2019506863A (en)
CN (1)	CN109310755A (en)
EA (1)	EA201891732A1 (en)
WO (1)	WO2017136562A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108112254B (en)	2015-03-13	2022-01-28	西托姆克斯治疗公司	anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof
JP2020522486A (en)	2017-06-01	2020-07-30	サイトメックスセラピューティクスインコーポレイテッド	Activatable anti-PDL1 antibody and method of using the same
KR102678252B1 (en) *	2017-09-01	2024-06-26	쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드	Recombinant Bispecific Antibodies
WO2019168947A1 (en) *	2018-02-28	2019-09-06	Ap Biosciences, Inc.	Bifunctional proteins combining checkpoint blockade for targeted therapy
UY38251A (en)	2018-06-01	2019-12-31	Novartis Ag	BINDING MOLECULES AGAINST BCMA AND USES OF THEM
US12583932B2 (en)	2018-11-16	2026-03-24	Virtuoso Binco, Inc.	CD38 and ICAM1 antibodies and uses thereof
CN111196856A (en) *	2018-11-19	2020-05-26	三生国健药业（上海）股份有限公司	anti-HER 2/PD1 bispecific antibodies
CN111196855B (en) *	2018-11-19	2022-11-15	三生国健药业（上海）股份有限公司	anti-EGFR/PD-1 bispecific antibodies
JP7148037B2 (en)	2018-12-03	2022-10-05	イミューンオンコバイオファーマシューティカルズ（シャンハイ）インコーポレイテッド	Recombinant proteins targeting PD-L1 and VEGF
CN109776683B (en) *	2019-03-19	2020-04-07	益科思特(北京)医药科技发展有限公司	Bispecific antibody and preparation method and application thereof
KR20220024729A (en) *	2019-06-24	2022-03-03	노파르티스 아게	Dosage regimens and combination therapies for multispecific antibodies targeting B-cell maturation antigens
AU2019461286B2 (en)	2019-08-09	2024-01-04	Akeso Biopharma, Inc	Anti-VEGF-anti-PD1 bispecific antibody with new-type structure
CN110498857B (en) *	2019-08-09	2022-09-09	安徽瀚海博兴生物技术有限公司	An anti-VEGF-anti-PD1 bispecific antibody
CN110563849B (en) *	2019-08-09	2022-09-09	安徽瀚海博兴生物技术有限公司	An anti-VEGF-anti-PD1 bispecific antibody
CN110760517B (en) *	2019-10-09	2022-04-29	天津大学	Antagonistic PD-1 camelid antibody analog AP gene and protein and application
CN113563473A (en) *	2020-04-29	2021-10-29	三生国健药业（上海）股份有限公司	Tetravalent bispecific antibody, preparation method and application thereof
CN113754773A (en) *	2020-06-02	2021-12-07	三生国健药业（上海）股份有限公司	Bispecific antibody for resisting PD1 XPDL 1
CN113754772A (en) *	2020-06-02	2021-12-07	三生国健药业（上海）股份有限公司	Bispecific antibody for resisting PDL1 XKDR
CN114106190B (en) *	2020-08-31	2025-04-08	普米斯生物技术(珠海)有限公司	An anti-VEGF/PD-L1 bispecific antibody and its use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014055996A2 (en) *	2012-10-05	2014-04-10	Kadmon Corporation, Llc	Rho kinase inhibitors
WO2015109124A2 (en) *	2014-01-15	2015-07-23	Kadmon Corporation, Llc	Immunomodulatory agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005051299A2 (en) *	2003-11-19	2005-06-09	Dyax Corp.	Metalloproteinase-binding proteins
MX2009001110A (en) *	2006-08-03	2009-05-11	Vaccinex Inc	Anti-il-6 monoclonal antibodies and uses thereof.
US7935345B2 (en) *	2007-05-21	2011-05-03	Children's Hospital & Research Center At Oakland	Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
TWI812066B (en) *	2010-11-30	2023-08-11	日商中外製藥股份有限公司	Antibody having calcium-dependent antigen-binding ability
CN105884900A (en) *	2011-04-19	2016-08-24	梅里麦克制药股份有限公司	Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies
HRP20201595T1 (en) *	2011-11-28	2020-12-11	Merck Patent Gmbh	Anti-pd-l1 antibodies and uses thereof
WO2013181452A1 (en) *	2012-05-31	2013-12-05	Genentech, Inc.	Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
JP2016502502A (en) *	2012-10-05	2016-01-28	カドモンコーポレイション，リミティドライアビリティカンパニー	Treatment of eye diseases
WO2014209804A1 (en) *	2013-06-24	2014-12-31	Biomed Valley Discoveries, Inc.	Bispecific antibodies
WO2015066543A1 (en) *	2013-11-01	2015-05-07	Board Of Regents, The University Of Texas System	Targeting her2 and her3 with bispecific antibodies in cancerous cells

2017
- 2017-02-02 EA EA201891732A patent/EA201891732A1/en unknown
- 2017-02-02 WO PCT/US2017/016230 patent/WO2017136562A2/en not_active Ceased
- 2017-02-02 JP JP2018540412A patent/JP2019506863A/en active Pending
- 2017-02-02 CN CN201780021304.8A patent/CN109310755A/en active Pending
- 2017-02-02 EP EP17748163.7A patent/EP3411068A4/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014055996A2 (en) *	2012-10-05	2014-04-10	Kadmon Corporation, Llc	Rho kinase inhibitors
WO2015109124A2 (en) *	2014-01-15	2015-07-23	Kadmon Corporation, Llc	Immunomodulatory agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAN LU ET AL: "Abstract 572: A novel anti-PDL1 x anti-VEGFR2 bispecific antibody for enhanced antitumor immunity \| Cancer Research", 16 April 2016 (2016-04-16), pages Abstract 572, XP055653955, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/76/14_Supplement/572.short> [retrieved on 20191218] *
ERIN LARKINS ET AL: "Regulatory Issues: FDA U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy", THE ONCOLOGIST, 2015, pages 1320 - 1325, XP055653942, Retrieved from the Internet <URL:http://theoncologist.alphamedpress.org/content/20/11/1320.long> [retrieved on 20191218] *
GEORGE W. SLEDGE: "Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?", JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 2, 10 January 2015 (2015-01-10), US, pages 133 - 135, XP055653932, ISSN: 0732-183X, DOI: 10.1200/JCO.2014.58.1298 *
ROLAND E. KONTERMANN ET AL: "Bispecific antibodies", DRUG DISCOVERY TODAY, vol. 20, no. 7, July 2015 (2015-07-01), AMSTERDAM, NL, pages 838 - 847, XP055251363, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2015.02.008 *

Also Published As

Publication number	Publication date
WO2017136562A2 (en)	2017-08-10
JP2019506863A (en)	2019-03-14
WO2017136562A3 (en)	2017-09-28
CN109310755A (en)	2019-02-05
EA201891732A1 (en)	2019-02-28
EP3411068A2 (en)	2018-12-12

Legal Events

Date	Code	Title	Description
2017-08-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-11-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-11-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-12-12	17P	Request for examination filed	Effective date: 20180831
2018-12-12	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-12-12	AX	Request for extension of the european patent	Extension state: BA ME
2019-05-08	DAV	Request for validation of the european patent (deleted)
2019-05-08	DAX	Request for extension of the european patent (deleted)
2020-01-29	A4	Supplementary search report drawn up and despatched	Effective date: 20200108
2020-01-29	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/22 20060101ALI20191220BHEP Ipc: A61K 39/395 20060101AFI20191220BHEP Ipc: C07K 16/28 20060101ALI20191220BHEP
2020-12-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2021-01-20	18D	Application deemed to be withdrawn	Effective date: 20200808

Publication	Publication Date	Title
EP3411068A4 (en)	2020-01-29	Bispecific binding proteins for pd-l1 and kdr
IL283115A (en)	2021-06-30	Bispecific cd33 and cd3 binding proteins
ZA201808160B (en)	2021-08-25	Bispecific binding proteins and uses thereof
ZA201900347B (en)	2020-05-27	Bispecific proteins and methods for preparing same
IL260846B (en)	2022-10-01	Antigen binding proteins that bind pd-l1
GB201805963D0 (en)	2018-05-23	PD-L1 Binding Affirmers and Uses Related Thereto
PL3592769T3 (en)	2024-10-14	Antibodies against pd-l1
EP3244727A4 (en)	2018-10-31	Insecticidal proteins and methods for their use
SG11201803520PA (en)	2018-05-30	Antibodies specifically binding pd-1 and their uses
EP3097122A4 (en)	2017-09-20	Binding proteins and methods of use thereof
EP3218483A4 (en)	2018-07-18	Compounds and methods for the modulation of proteins
EP3140763A4 (en)	2018-02-07	Binding affinity prediction system and method
EP3147298A4 (en)	2017-12-06	Pd-l1 fusion protein and use thereof
EP3304942A4 (en)	2018-05-30	Method and apparatus for sharing application
EP3277817A4 (en)	2018-12-05	Compounds and methods for modulating tmprss6 expression
EP3341021A4 (en)	2019-03-13	Anti-alk antibodies and methods for use thereof
EP3302555A4 (en)	2018-07-11	Methods of using bispecific cd33 and cd3 binding proteins
EP3256163A4 (en)	2018-10-10	Methods and compositions for modulating lilr proteins
EP3554535A4 (en)	2020-10-21	Pd-l1 binding fibronectin type iii domains
EP3310011A4 (en)	2018-08-15	Load sharing method and related apparatus
EP3209695A4 (en)	2018-05-30	Cd83 binding proteins and uses thereof
EP3139955A4 (en)	2018-06-27	Fusion proteins for treating cancer and related methods
EP3377101A4 (en)	2019-08-07	Methods and compositions for binding vegf
EP3146985A4 (en)	2017-12-06	Graft material and method for preparing same
HK40027234A (en)	2021-01-15	Compositions and methods for expressing otoferlin